This is to enhance their R&D arm with focus on CVD but this is not going to help them in short or long term with the declining revenues. This is one of their smaller acquisitions. There will be more. Stay tuned.
It's interesting that they are placing bets in the space. Only proves that cholesterol is still a major focus. I don't see anything negative by it. This drug, if it works won't hit the shelves until the Reduce-IT trial is completed.